DT-109

DT-109 is a novel, orally active tripeptide drug candidate developed for the treatment of non-alcoholic steatohepatitis (NASH) and other metabolic diseases. In preclinical studies involving both mice and non-human primates, DT-109 has demonstrated efficacy in reversing hepatic fat accumulation, preventing fibrosis progression, and improving liver histology associated with NASH. The compound acts by stimulating fatty acid degradation, increasing antioxidant formation (notably glutathione), reducing inflammation, modulating the gut microbiome, and inhibiting production of lithocholic acid—a toxic secondary bile acid linked to liver disease. Additionally, DT-109 stimulates intestinal GLP-1 release and increases insulin secretion from pancreatic β cells in vitro. It has also shown glucose-lowering effects in type 2 diabetes models and reduced atherosclerosis plaque burden in preclinical studies. The drug was invented at the University of Michigan and is being developed by Diapin Therapeutics[1][2][3][4][5][6].